Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
PALATIN TECHNOLOGIES INC (PTN) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
05/16/2023 8-K Quarterly results
Docs: "Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update"
11/14/2022 8-K Quarterly results
Docs: "Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update"
09/22/2022 8-K Quarterly results
Docs: "Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update"
05/17/2022 8-K Quarterly results
02/15/2022 8-K Quarterly results
Docs: "Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update"
09/29/2021 8-K Quarterly results
Docs: "Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update ● Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 ● Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 ● $60.1 Million in Cash and Cash Equivalents at June 30, 2021 – Projected Cash Runway Through Calendar 2022 ● Teleconference and Webcast today at 11:00 a.m. Eastern Time CRANBURY, NJ, September 29, 2021/PRNewswire/ -- Palatin Technologies, Inc., , a biopharmaceutical company developing first-in-class medicines ba..."
02/17/2021 8-K Quarterly results
11/17/2020 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update ● Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 ● Phase 2 Clinical Results of PL9643 for the Treatment of Dry Eye Disease on Track for December 2020 ● $86.6 Million in Cash and Cash Equivalents as of September 30, 2020 ● Conference Call Today at 11:00 AM ET CRANBURY, NJ – November 17, 2020 – Palatin Technologies, Inc. , a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its first quarter ended September 30, 2020..."
09/28/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights ● Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 ● $89 Million in Cash at March 31, 2020 ● Teleconference and Webcast to be held on May 12, 2020 CRANBURY, NJ – May 12, 2020 – Palatin Technologies, Inc. , a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its third quarter ended March 31, 2020. Third Quarter Fiscal Year 2020 Financial Highlights ● Net loss of $ million, compared to $ million for the comparable quarter of 2019; ● Operating expenses of $5.7 mil..."
02/11/2020 8-K Quarterly results
11/13/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019 CRANBURY, NJ – May 9, 2019 – Palatin Technologies, Inc. , a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2019. Recent Highlights and Program Updates Female Sexual Dysfunction / Vyleesi™ ● Vyleesi, the trade name for bremelanotide - Under development for Hypoactive Sexual Desire Disorder : ● The Prescription Drug User Fee Act date for completion of FDA review of the Vyleesi New Drug Application is June 23, 2019 ● The U.S. Food and Drug Administra..."
02/12/2019 8-K Quarterly results
09/13/2018 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, NJ – September 13, 2018 – Palatin Technologies, Inc. , a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2018. “The last year has been very productive for Palatin, most notably the acceptance of the Vyleesi™ NDA by the FDA,”..."
05/15/2018 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018 CRANBURY, NJ – May 15, 2018 – Palatin Technologies, Inc. , a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2018. Recent Highlights ● Bremelanotide - Under development for Hypoactive Sexual Desire Disorder : ● March 2018 – our exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. , submitted a New Drug Application to the U.S. Food and Drug Administration for bremelanotide for the treatment of HSDD in premenopausal women. ● If a..."
02/12/2018 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018 CRANBURY, NJ – February 12, 2018 – Palatin Technologies, Inc. , a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2017. Recent Highlights ● Bremelanotide - Under development for Hypoactive Sexual Desire Disorder : ● Entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. in November 2017 for exclusive rights to develop and commercialize bremelanotide in the Republic of Korea. ● Received $417,500 in December 2017, consisting of ..."
11/13/2017 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on November 13, 2017 CRANBURY, NJ – November 13, 2017 – Palatin Technologies, Inc. , a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2017. Recent Highlights ● Bremelanotide - Under development for Hypoactive Sexual Desire Disorder : – Entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. , a subsidiary of Shanghai Fosun Pharmaceutical Co., Ltd in September 2017 for exclusive rights to develop and commercialize brem..."
09/25/2017 8-K Quarterly results
05/16/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
11/15/2016 8-K Form 8-K - Current report
05/17/2016 8-K Form 8-K - Current report
02/16/2016 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on February 16, 2016"
11/12/2015 8-K Quarterly results
Docs: "Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015"
09/21/2015 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results"
05/13/2015 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on May 13, 2015"
02/13/2015 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on February 13, 2015"
11/18/2014 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014"
09/09/2014 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Results"
05/13/2014 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on May 13, 2014"
02/18/2014 8-K Quarterly results
Docs: "Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy